Aim: To evaluate the survival of patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE) with drug-eluting beads, to evaluate the correlation of the length of survival with the factors related to primary liver tumour and factors related to interventions, treatment and response to treatment. Another aim is to evaluate the interobserver variability of measurement in the evaluation response to treatment using RECIST and mRECIST criteria and volumetry. Methods: The total of 49 patients treated in the University Hospital Brno with the diagnosis of HCC were included in this retrospective study. The tumour range was evaluated on the CT/MR input and output by two independent doctors. The survival of the patients was evaluated since the date of the first TACE, in relation to well-known factors effecting the treatment of HCC. The survival was evaluated by the Kaplan-Meier method and the differences in survival by the logrank test. The interobserver variability was determined by using Pearson and Spearman correlation coefficient. Results: The strongest correlation has been proven between the length of survival and determination of the viable part of tumour using volumetry and the ratio viable/aviable parts of the tumour. The median of survival since the first performed TACE is 17.1 months. The evaluation of the response to treatment using RECIST and mRECIST criteria and volumetry has been proven with statistically significant small interobserver variability; however, the best result was achieved by using volumetric analysis. Conclusion: TACE with drug-eluting beads is a modern method of treatment of HCC. When evaluating the response to treatment, it is convenient to use volumetric analysis.